Targeted drug delivery is critical for the success of many therapeutic efforts in immuno-therapy, oncology, gene therapy, etc. The surface charge of API-loaded nanoparticles or microparticles can be a governing factor in drug targeting. Phosphorex has engineered the surface of polymeric particles for a variety of targeting applications and created several delivery platforms.
ZetaUltraTM are PLGA nanoparticles with a positive surface charge. A drug molecule can be loaded into this carrier to facilitate specific targeting purposes. Typically, ZetaSupreme particles have Zeta potential values of around + 30 mV.
ZetafinityTM are PLGA nanoparticles specially designed to have highly negatively surface charge – with a Zeta potential value of -35 mV or less. Research has found that this type of particles targets immunologically important cells to enable immunotherapy.
In certain drug delivery applications, it is required that the surface of drug loaded particles to be non-charged, i.e. having a near zero Zeta potential. ZetaNeutraTM particles were engineered to have neutral surface to meet this specific requirement.
NanofinityTM are very small PLGA nanoparticles (50-150 nm) encapsulating biologic and small molecule drugs and leveraging the enhanced permeability and retention (EPR) effect.
In addition to the platform technologies specifically for targeted delivery, Phosphorex also developed a carrier system for topical or transdermal delivery.
DermaDropletsTMconsists of oil droplets in which drug molecules are dissolved. The droplets are stabilized by hydrophilic excipients and remain stable until the formulation is applied either topically or transdermally. This platform provides a unique vehicle that enables the delivery of poorly soluble APIs in aqueous formulations with enhanced bioavailability, controlled release and stability.